The introduction of ADCs into frontline ovarian cancer treatment creates a new challenge: conflicting biomarkers. A patient's tumor might be positive for both HER2 (an ADC target) and a BRCA mutation (a PARP inhibitor target), forcing clinicians to choose between two effective targeted therapies without clear guidance.

Due to a shortage of genetic counselors and patient access issues, the traditional referral workflow is being inverted. Oncologists now frequently order genetic tests themselves and then refer patients with positive findings to a counselor. This pragmatic shift ensures testing isn't missed due to scheduling delays or patient travel burdens.

The podcast reveals a philosophical split among oncologists. One side advocates for universal germline testing to identify all carriers for therapeutic and preventative reasons. The other, more selective approach argues for testing only when the result will directly influence an immediate treatment decision.

While PARP inhibitors show some effect in all patients, clinical data revealed a significant survival advantage only in the HRD-positive subgroup. This has led to an FDA restriction, making biomarker testing a prerequisite for this class of drugs.

The selection between PARP inhibitors like olaparib and niraparib is not one-size-fits-all. It's a personalized decision based on patient preference for dosing frequency (once vs. twice daily), tolerance for side effects like hypertension, and potential drug-drug interactions.

Tissue may become insufficient or necrotic after neoadjuvant chemotherapy, leading to failed molecular tests. Securing tissue for comprehensive biomarker analysis at the initial diagnosis is crucial to guide treatment decisions, including PARP inhibitor eligibility.

Achieving remission in ovarian cancer is common, but it's often not sustainable. The strategic use of maintenance therapies, like oral PARP inhibitors, is essential to prolonging the cancer-free period and is a central focus of modern treatment.

Dr. Wander notes a strong clinical correlation: a BRCA mutation found on a somatic NGS test with a ~30-60% allelic frequency is very likely germline. However, this cannot replace a dedicated, CLIA-approved germline test for formal diagnosis and family counseling. This distinction is crucial for patient management and has genetic implications for relatives.

Recent trial data shows that patients with somatic BRCA1/2 mutations (found only in the tumor, not inherited) can achieve significant responses to PARP inhibitors. This finding supports routine tumor genomic testing to identify more candidates for this targeted therapy beyond just those with germline mutations.